English articles
- Did Lilly's Oral Drug Ignite the Market?
- A Historic Moment: The Next Century-Defining Drug Has Arrived
- Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know
- Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?
- The Valley of Death in Innovative Drug Development
- The 2026 Q2 Drug Catalysts Biotech Readers Need to Know
- The Fall of Two Star Biotechs
- Investors Should Pay Attention to the Autoimmune Mega-Drug Race
- The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?
- Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase
- Why Did the Market Like This Company More After a Clinical Failure?
- When Should a Company Decisively Abandon a Clinical Trial?
- A New Drug Finally Arrives for This Group of Rare-Disease Patients
- The Abivax Story: How a European Biotech Became a 14-Fold Market Myth
- While the US CDC Was Still Looking for a Director
- The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means
- How Far Are We From a Real Anti-Aging Drug?
- Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?
- After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?
- Can Merck Build Another Oncology Empire?
- Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?
